Given that TGFβ protects tumour cells from the immune system and cancer cells stimulate immune checkpoint inhibitory receptors, anti-tumourigenic immunotherapies are being developed to stimulate immune-mediated destruction of tumour cells (Bai et al., 2019). The gene discussed is TGFB1; the disease is neoplasm.